James Dugan MD
Blood Banking & Transfusion Medicine, Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Novant Health Cancer Institute
Join to View Full Profile
3333 Silas Creek ParkwayWinston Salem, NC 27103
Phone+1 336-718-5570
Dr. Dugan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. James Dugan is a malignant hematologist in Winston Salem, NC and is affiliated with Novant Health Cancer Institute at Forsyth Medical Center. He received his medical degree from University of Nevada Reno School of Medicine, completed Med/Peds residency at The Ohio State, and Heme/Onc Fellowship at the University of Colorado. He has been in practice 10 years. He specializes in acute myeloid leukemia, transplant and cellular therapy, and clinical research with phase 1 trial management. He has 10 publications and over 50 citings.
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2016 - 2019
Ohio State University HospitalResidency, Internal Medicine/Pediatrics, 2012 - 2016
University of Nevada, Reno School of MedicineClass of 2012
University of OregonPhilosophy and Biology, 2000 - 2005
Certifications & Licensure
NC State Medical License 2019 - 2025
OH State Medical License 2014 - 2021
CO State Medical License 2017 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome Start of enrollment: 2021 Feb 08
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage Start of enrollment: 2019 Nov 22
- A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Start of enrollment: 2021 Jul 30
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsThe effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.Jan S Moreb, Lori Lantos, Franklin Chen, Kathleen Elliott, James Dugan
Transfusion and Apheresis Science. 2023-12-01 - 2 citationsCOVID-19 in patients with Acute Leukemia: two cases with different outcomes.Venkat Rajasurya, Kathleen Elliott, James Dugan, Jan S. Moreb
Leukemia Research Reports. 2021-01-01 - 9 citationsHematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.Allison H. West, Hayley Knollman, James Dugan, Donald Hedeker, Elisabeth A Handorf
Cancer Medicine. 2019-09-01
Abstracts/Posters
- Bone marrow cellularity and recovery of blood counts after venetoclax and azacitadine in elderly acute myeloid leuekmia patients unfit for induction chemotherapyJames P Dugan, Acute Leukemia Forum, Newport Beach, CA, 2018
- Girl on fire: a case of atypical mycobacterium and hemophagoytic lymphohistiocytosisJames P Dugan, American College of Physcians, Ohio Chapter, Columbus, Ohio, 2016
- Epstein-Barr virus kinase-targeted therapy for primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD)James P Dugan, American Society for Hematology, 2014
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
